Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bladder-conserving comprehensive treatment with Tislelizumab plus GC for muscle-invasive bladder cancer
ChiCTR2400085414Phase 2Completed
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma of the bladder (TCC), sponsored by Second Hospital of Lanzhou University. Primary endpoint: 1-year bladder-conserving survival rate. Started Jun 2024; status: completed.
02
Drugs
tislelizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2400085414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085414.